Skip to main content

Advertisement

SpringerLink
Log in

Toxicity associated to radiotherapy treatment in lung cancer patients

  • Reviews
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Radiation therapy in combination with other treatments, such as chemotherapy, increases loco-regional control and survival in patients with lung cancer. Nevertheless, the subsequent toxicity of this treatment occurs in up to 37% of the irradiated patients. Some factors related to the patient, including performance status, pulmonary function tests (FEV1, DCLO), tumour site, as well as treatment-related factors such as radiation dose, fractionation and addition of chemotherapy, can be related to the risk of pulmonary toxicity. With the advent of tridimensional conformal radiotherapy (3DCRT), dose-volume histograms can be generated to assess the dose received by the organs at risk. Volume dose (Vdose), mean lung dose (MLD) and normal tissue complication probability (NTCP) are the dosimetric parameters most frequently used. The possible relationship between these parameters and clinical and anatomical factors has to be considered. Steroid treatment should be started soon in case of pneumonitis to avoid the development of late pulmonary fibrosis. Finally, some pharmacological agents to prevent radiation-related pneumonitis are under investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Rodrigues G, Lock M, D’souza D et al (2004) Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review. Radiother Oncol 71:127–138

    Article  PubMed  Google Scholar 

  2. Kong FM, Haken RT, Eisbruch A et al (2005) Non-small-cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol 32[Suppl 3]:S42–54

    Article  PubMed  CAS  Google Scholar 

  3. Tsoutsou P, Koukorakis M (2006) Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 66:1281–1293

    PubMed  Google Scholar 

  4. Marks L, Yu X, Vujaskovic Z et al (2003) Radiationinduced lung injury. Semin Radiat Oncol 13:333–345

    Article  PubMed  Google Scholar 

  5. Wall RJ, Schnapp LM (2006) Radiation pneumonitis. Respir Care 51:1255–1260

    PubMed  Google Scholar 

  6. Mehta V (2005) Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63:5–24

    Article  PubMed  Google Scholar 

  7. De Jaeger K, Seppenwoolde Y, Boersma LJ et al (2003) Pulmonary function following high dose radiotherapy of NSCLC. Int J Radiat Oncol Biol Phys 55:1331–1340

    Article  PubMed  Google Scholar 

  8. Hope A, Lindsay P, El Naqa I et al (2006) Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 65:112–124

    Article  PubMed  Google Scholar 

  9. Byhardt RW, Scott C, Sause WT et al (1998) Response, toxicity, failure patterns, and survival in five RTOG trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 42:469–478

    Article  PubMed  CAS  Google Scholar 

  10. Roach M, Gandara DR, You HS et al (1995) Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13:2606–2612

    PubMed  Google Scholar 

  11. Senan S, De Ruysscher D, Giraud PH et al (2004) Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 71:139–146

    Article  PubMed  Google Scholar 

  12. Gaspar LE, Mc Coy J, Kelly K et al (2006) Analysis of V20 and Radiation Pneumonitis on SWOG0023: A phase III Trial of Concurrent Chemoradiation and Docetaxel Consolidation in Stage III Nonsmall Cell Lung Cancer. Int J Radiat Oncol Biol Phys 66[suppl 3]:S61–62

    Google Scholar 

  13. Oetzel D, Schraube P, Hensely F et al (1995) Estimations of pneumonitis risk in 3D treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33:455–460

    Article  PubMed  CAS  Google Scholar 

  14. Armstrong J, Raben A, Zelefsky M et al (1997) Promising survival with three dimensional conformal radiation therapy for non small cell lung cancer. Radiother Oncol 44:17–22

    Article  PubMed  CAS  Google Scholar 

  15. Kwa SLS, Theuws JCM, Wagenaar A et al (1998) Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. Radiother Oncol 48:61–69

    Article  PubMed  CAS  Google Scholar 

  16. Graham M, Purdy J, Emami B et al (1999) Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for NSCLC. Int J Radiat Oncol Biol Phys 45:323–329

    Article  PubMed  CAS  Google Scholar 

  17. Hernando M, Marks L, Bentel G et al (2001) Radiation induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51:650–659

    Article  PubMed  CAS  Google Scholar 

  18. Yorke ED, Jackson A, Rosenzweig KE et al (2002) Dose-volume factors contributing to the incidence of radiation pneumonitis in non small cell lung cancer patients treated with 3D conformal radiation therapy. Int J Radiat Oncol Biol Phys 54:329–339

    Article  PubMed  Google Scholar 

  19. Tsujino K, Hirota S, Endo M et al (2003) Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55:110–115

    Article  PubMed  Google Scholar 

  20. Claude L, Pérol D, Ginestet Ch et al (2004) A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol 71:175–181

    Article  PubMed  Google Scholar 

  21. Wang Sh, Liao Z, Wei X et al (2006) Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis in patients with non small cell lung cancer treated with concurrent chemotherapy and 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 66:1399–1407

    PubMed  CAS  Google Scholar 

  22. Miller K, Shafman T, Marks L et al (2004) A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer. Semin Radiat Oncol 14:298–307

    Article  PubMed  Google Scholar 

  23. Yorke ED, Jackson A, Rosenzweig KE et al (2004) Correlation of dosimetric factors and radiation pneumonitis incidence for non small cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 60:S240

    Article  Google Scholar 

  24. Seppenwoolde Y, Lebesque JV, De Jaeger K et al (2003) Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 55:724–735

    Article  PubMed  Google Scholar 

  25. Schallenkamp JM, Miller RC, Brinkmann DH et al (2007) Incidence of radiation pneumonitis after thoracic irradiation: dose-volume correlates. Int J Radiat Oncol Biol Phys 67:410–416

    PubMed  Google Scholar 

  26. Belderbos J, De Jaeger K, Heemsbergen W et al (2003) First results of a phase I/II dose escalation trial in non-small cell lung cancer using 3D conformal radiotherapy. Radiother Oncol 66: 119–126

    Article  PubMed  Google Scholar 

  27. Bradley J, Graham MV, Winter K et al (2005) Toxicity and outcome results of RTOG 9311: a phase I–II dose-escalation study using 3D conformal radiotherapy in patients with inoperable nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys 61:318–328

    Article  PubMed  Google Scholar 

  28. Kong F, Hayman J, Griffith K et al (2006) Final toxicity results of a radiation-dose escalation study in patients with non-small cell lung cancer: predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65:1075–1086

    Article  PubMed  Google Scholar 

  29. Socinski M, Morris D, Halle J et al (2004) Induction and concurrent chemotherapy with highdose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 22:4341–4350

    Article  PubMed  CAS  Google Scholar 

  30. Marks L, Munley M, Bentel G et al (1997) Physical and biological predictors of changes in whole lung function following thoracic irradiation. Int J Radiat Oncol Biol Phys 39:563–570

    Article  PubMed  CAS  Google Scholar 

  31. Fu XL, Huang H, Bentel G et al (2001) Predicting the risk of symptomatic radiation induced lung injury using the physical and biologic parameters V30 Gy and TGF-β. Int J Radiat Oncol Biol Phys 50:899–908

    Article  PubMed  CAS  Google Scholar 

  32. De Jaeger K, Seppenwoolde Y, Harm H et al (2004) Significance of plasma transforming growth factor-β levels in radiotherapy for nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 58:1378–1387

    Article  PubMed  CAS  Google Scholar 

  33. Rancati T, Ceresoli GL, Gagliardi G (2003) Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study. Radiother Oncol 67:89–94

    Article  Google Scholar 

  34. Gopal R (2005) Pulmonary toxicity associated with the treatment of non-small-cell lung cancer and the effects of cytoprotective strategies. Semin Oncol 32[Suppl 3]:S55–59

    Article  PubMed  CAS  Google Scholar 

  35. Komaki R, Soo Lee J, Milas L et al (2004) Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58:1369–1377

    Article  PubMed  CAS  Google Scholar 

  36. Werner-Wasik M, Scott C, Movsas B et al (2003) Amifostine as mucosal protectant in patients with locally advanced non small cell lung cancer receiving intensive chemotherapy and thoracic radiotherapy: results of the RTOG 98-01 study. Int J Radiat Oncol Biol Phys 57:S216

    Google Scholar 

  37. Tsujino K, Hirota S, Kotani Y et al (2006) Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage small-cell lung cancer: dose-volume histogram analysis and comparison with conventional chemoradiation. Int J Radiat Oncol Biol Phys 64:1100–1105

    Article  PubMed  Google Scholar 

  38. Saunders M, Dische S, Barrett A et al (1997) Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: a randomized multicentre trial. CHART Steering Committee. Lancet 350:161–165

    Article  PubMed  CAS  Google Scholar 

  39. Sekine I, Sumi M, Ito Y et al (2006) Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother Oncol 80:93–97

    Article  PubMed  CAS  Google Scholar 

  40. Ward WF, Lin PJ, Wong PS et al (1993) Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high resolution computed tomography. Radiat Res 135:81–87

    Article  PubMed  CAS  Google Scholar 

  41. Molteni A, Moulder JE, Cohen EF et al (2000) Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Oncol Biol Phys 76: 523–532

    CAS  Google Scholar 

  42. Ozturk B, Egehan I, Atavci S et al (2004) Pentoxifylline in prevention of radioinduced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys 58:213–219

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Radioterápica, Hospital Universitario de la Princesa, C/ Diego de León, 62, ES-28006, Madrid, Spain

    M. López Rodríguez & L. Cerezo Padellano

Authors
  1. M. López Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Cerezo Padellano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. López Rodríguez.

Rights and permissions

Reprints and permissions

About this article

Cite this article

López Rodríguez, M., Cerezo Padellano, L. Toxicity associated to radiotherapy treatment in lung cancer patients. Clin Transl Oncol 9, 506–512 (2007). https://doi.org/10.1007/s12094-007-0094-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-007-0094-4

Key words

Search

Navigation